People negotiating in a meeting room
(Source: Adobe Stock)
  • ME Therapeutics (CSE:METX) has revealed it has entered into a collaboration with NanoVation Therapeutics
  • The collaboration aims to test the delivery and efficacy of mRNA-based drug candidates targeting myeloid cells, which are components of the innate immune system
  • ME Therapeutics aims to enhance the efficacy of myeloid cell-delivered mRNA therapeutics in vivo to develop potential new cancer therapies
  • Shares of ME Therapeutics are up 0.820 per cent to C$4.94 as of 9:29 am ET

ME Therapeutics (CSE:METX) has revealed it has entered into a collaboration with NanoVation Therapeutics.

The company stated in a news release that the collaboration aims to test the delivery and efficacy of mRNA-based drug candidates targeting myeloid cells, which are components of the innate immune system.

ME Therapeutics stated it also aims to enhance the efficacy of myeloid cell-delivered mRNA therapeutics in vivo to develop potential new cancer therapies by leveraging NanoVation Therapeutics’ lipid nanoparticle platforms.

To target immune cells, NanoVation has designed and optimized its long-circulating LNP technology.

“We believe that nucleic acid-based medicines are the next wave in the treatment of cancer and other diseases,” Salim Dhanji, CEO of ME Therapeutics, said in a statement. “We are thrilled to collaborate with NanoVation Therapeutics as [it] has deep expertise in LNP delivery, which will be critical for unlocking new medicines by enabling precise delivery and targeting of mRNA to key targets such as myeloid cells.”

The initial stage of this collaboration will involve testing the delivery and efficacy of two undisclosed target mRNAs to tumor-associated myeloid cells in vivo in a mouse colon cancer model.

Based out of Vancouver, ME Therapeutics is a preclinical-stage biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer.

Shares of ME Therapeutics Holdings Inc. (CSE:METX) are up 0.820 per cent to C$4.94 as of 9:29 am ET.

Join the discussion: Find out what everybody’s saying about this stock on the ME Therapeutics Holdings Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

(Top image: Adobe Stock)



More From The Market Online
AI-generated image of gold bars beside a computer with a financial chart.

The Market Online’s Weekly Gold Report – July 24, 2024

The Market Online reviews the week's top gold stories, gold prices, gold company news and trending gold stocks.
Periodic table concept with uranium element is glowing among black cubes

Fueling the Future: Uranium market activity for the week of July 22

In this week's uranium market update, companies such as Centrus Energy, Aero Energy, Myriad Uranium and SKRR Exploration made headlines.
Bank of Canada Governor Tiff Macklem and Senior Deputy Governor Carolyn Rogers

Bank of Canada cuts interest rate: 4 investment catalysts to consider

The Bank of Canada cut rates for a second meeting in a row thanks to favourable inflation, unemployment and consumer spending trends.
A worker using a pickaxe to extract uranium ore from a rock face.

Top 9 Canadian uranium stocks to watch

Canada ranks second in terms of uranium production globally and hosts some of the top uranium mining companies in the world.